KaliVir, a biotech company developing multi-mechanistic oncolytic viral immunotherapy programmes, has unveiled its state-of-the-art GMP cleanroom facility to manufacture its pipeline of oncolytic viruses.
The US-based company has already executed the inaugural manufacturing run for its lead clinical candidate, VET3-TGI.
KaliVir's GMP manufacturing facility includes a cleanroom spanning over 1,000 sqft.
The opening of our GMP facility marks a pivotal moment in our journey to advance transformative cancer therapies
The facility is equipped with the iCellis 500 bioreactor, hyper-stack, filtration and chromatography capabilities and is supported by KaliVir’s comprehensive quality, process development and analytical development capabilities.
In addition to manufacturing its own oncolytic viruses, KaliVir has the capability to provide production services for select biotechnology companies worldwide.
Steve Thorne, Chief Scientific Officer and founder of KaliVir Immunotherapeutics, said: “The opening of our GMP facility marks a pivotal moment in our journey to advance transformative cancer therapies. This state-of-the-art facility underscores our dedication to meeting the highest manufacturing standards and ensuring the seamless development of groundbreaking oncolytic viral immunotherapies from conception to the clinic. We are proud of the progress we've made and excited about the potential impact our innovative treatments can have in the fight against cancer."
